Clinical Trials
6 trialsNCT05441514 2026-05-05
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT05102370 2026-01-27
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03515512 2025-10-14
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT04281498 2025-02-04
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04522895 2024-09-19
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Heinrich-Heine University, Duesseldorf
Phase 2 Completed